ERNA Stock Surged 60% Today – Here’s Why Retail Is Buzzing About Ernexa’s Ovarian Cancer Trial Results

• Management said the outcome exceeded the company’s expectations.
• The biotech firm also announced plans to advance the therapy toward a human trial.
• Ernexa had recently implemented a 1-for-25 reverse stock split.

Shares of Ernexa Therapeutics (ERNA) surged 60% on Wednesday, as investors cheered promising preclinical results for its lead cell therapy, fueling optimism about its potential in advanced ovarian cancer treatment.

The biotech firm announced plans to advance the therapy toward a first-in-human trial in patients with advanced ovarian cancer.

ERNA-101 Trial Beats Expectations

In combination with PD-1 blockade immunotherapy, ERNA-101 achieved complete tumor clearance and 100% long-term survival in syngeneic ovarian cancer models, using mice, significantly outperforming either treatment alone.

The study showed that ERNA-101 helped reshape the tumor microenvironment. This change boosted the activity of cancer-fighting T cells and increased immune cell infiltration into tumors. The treatment also reduced overall tumor burden and disease-related complications.

Management said the outcome exceeded the company’s expectations and the results potentially shift treatment outcomes in ovarian cancer.

“This approach may also extend beyond ovarian cancer, with the potential to drive meaningful responses across other immunologically ‘cold’ solid tumors characterized by highly suppressive tumor microenvironments. We believe ERNA-101 has the potential to become a foundational therapy in combination regimens, significantly expanding treatment effectiveness,” said Sanjeev Luther, President and CEO.

Peers Update

Ernexa’s trial comes on the heels of Zentalis Pharmaceuticals’ (ZNTL) interim results from its study of Azenosertib oral therapy for platinum-resistant ovarian cancer. The company selected a 400 mg once-daily dose after it delivered higher response rates than the 300 mg dose with similar safety.

That prompted Guggenheim to raise Zentalis’ price target and maintain a ‘Buy’ rating. The firm expressed confidence in the drug’s chances of success.

Prior to that, the FDA approved Corcept Therapeutics’ (CORT) Relacorilant drug in combination with chemotherapy drug nab-paclitaxel, for advanced ovarian-related cancers, months ahead of schedule.

How Did Retail Traders React To ERNA’s Update?

Retail sentiment for ERNA on Stocktwits turned ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.

One bullish user expects a 200% rally following the news.

Another user highlighted the strength behind today’s update.

The company implemented a 1-for-25 reverse stock split earlier this week.

Read also: TGTX Stock Hits Fresh 52-Week High – Here’s Why Retail Is Bullish Despite Q1 Earnings Miss

For updates and corrections, email newsroom[at]stocktwits[dot]com.